Your browser doesn't support javascript.
loading
Effectiveness of CoronaVac in the prevention of COVID-19, a test-negative case-control study in Brazil.
Luna, Expedito J A; Moraes, José C; Roediger, Manuela A; Miranda, Erique J F P; Braga, Patrícia E; França, João I D; Pacheco, Pedro H M; de Lima, Marcos Alves; Ragiotto, Lucas; Barros, Eliana N C.
Afiliación
  • Luna EJA; Universidade de São Paulo, Faculdade de Medicina, São Paulo, SP, Brazil. Electronic address: eluna@usp.br.
  • Moraes JC; Faculdade de Ciências Médicas da Santa Casa, São Paulo, SP, Brazil.
  • Roediger MA; Instituto Butantan, São Paulo, SP, Brazil.
  • Miranda EJFP; Instituto Butantan, São Paulo, SP, Brazil.
  • Braga PE; Instituto Butantan, São Paulo, SP, Brazil.
  • França JID; Instituto Butantan, São Paulo, SP, Brazil.
  • Pacheco PHM; Instituto Butantan, São Paulo, SP, Brazil.
  • de Lima MA; Instituto Butantan, São Paulo, SP, Brazil.
  • Ragiotto L; Instituto Butantan, São Paulo, SP, Brazil.
  • Barros ENC; Instituto Butantan, São Paulo, SP, Brazil.
Braz J Infect Dis ; 28(5): 103856, 2024.
Article en En | MEDLINE | ID: mdl-39117300
ABSTRACT
The present study aimed to evaluate the effectiveness of two doses of CoronaVac in preventing SARS-CoV-2 symptomatic disease with virological confirmation, as well as in the prevention of COVID-19 moderate and severe cases. A test-negative unmatched case-control design was used, in which cases were patients with suspected COVID-19 (presenting at least two of the following symptoms fever, chills, sore throat, headache, cough, runny nose, olfactory or taste disorders) with virological confirmation, and controls were those whose SARS-CoV-2 test was negative. As for exposure, participants were classified as unvaccinated, or vaccinated with a complete schedule. Suspected COVID-19 cases were identified from March to November 2021, in two cities located in the State of São Paulo, Brazil. All participants signed the Informed Consent Form before enrollment. RT-PCR results and vaccination data were obtained from the local surveillance systems. Up to two phone calls were made to obtain information on the outcome of the cases. A total of 2981 potential participants were screened for eligibility, of which 2163 were included, being 493 cases and 1670 controls. Vaccination, age, the reported contact with a COVID-19 suspected or confirmed case in the 14 days before symptoms onset, and the educational level were the variables independently associated with the outcome. The adjusted vaccine effectiveness for symptomatic COVID-19 (AVE) was 39.0 % (95 % CI 6.0-60.0 %). The AVE in the prevention of moderate and severe disease was 91.0 % (95 % CI 76.0-97.0 %). Our results were influenced by the waning of the Gamma variant, in the second trimester of 2021, followed by the increase in vaccination coverage, and a drop in the number of cases in the second half of the year. The study demonstrated the high effectiveness of CoronaVac in preventing moderate/severe COVID-19 cases.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do sul / Brasil Idioma: En Revista: Braz J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article Pais de publicación: Brasil

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do sul / Brasil Idioma: En Revista: Braz J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article Pais de publicación: Brasil